Johns Hopkins ABX Guide
Daclatasvir
INDICATIONS
WHO
WHO
- In combination with sofosbuvir for the treatment of chronic HCV infection, genotypes 1–6.
- WHO recommends SOF/DCV as a pangenotypic regimen for adults, adolescents, and children ≥3 years.
- The original branded product is no longer marketed in the U.S.
- Daclatasvir remains widely used internationally as a generic.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: October 19, 2026
Citation
Tsai, Y. V, and Paul G Auwaerter. "Daclatasvir." Johns Hopkins ABX Guide, The Johns Hopkins University, 2026. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540654/all/Daclatasvir.
Tsai YV, Auwaerter PG. Daclatasvir. Johns Hopkins ABX Guide. The Johns Hopkins University; 2026. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540654/all/Daclatasvir. Accessed October 22, 2026.
Tsai, Y. V., & Auwaerter, P. G. (2026). Daclatasvir. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540654/all/Daclatasvir
Tsai YV, Auwaerter PG. Daclatasvir [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2026. [cited 2026 October 22]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540654/all/Daclatasvir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Daclatasvir
ID - 540654
A1 - Tsai,Y.,Pharm.D.
AU - Auwaerter,Paul,M.D.
Y1 - 2026/10/19/
BT - Johns Hopkins ABX Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540654/all/Daclatasvir
PB - The Johns Hopkins University
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
